Alzheimer's Disease and Related Neurodegenerative Disorders

CgA Therapeuticals is also developing CST-based therapeutics for Alzheimer's disease and related tauopathies.

Preclinical studies indicate that CST acts on several major processes associated with neurodegeneration, including abnormal tau phosphorylation and aggregation, amyloid pathology, neuroinflammation, and dysregulated adrenergic signaling. In experimental models, CST treatment has also been associated with improvements in cognitive and motor function.

These findings provide the foundation for developing CST and next-generation CST analogs as multi-pathway therapeutic candidates designed to address both proteinopathy and the inflammatory and neurochemical mechanisms that contribute to neurodegenerative disease progression.